Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
59,139.60 +803.19 (+1.38%) CMC Crypto 200
1,274.93 +4.19 (+0.33%)
Alkermes plc (ALKS)
After hours:
| Previous close | 24.01 |
| Open | 23.87 |
| Bid | 23.84 x 600 |
| Ask | 23.89 x 300 |
| Day's range | 23.39 - 23.99 |
| 52-week range | 22.01 - 33.71 |
| Volume | |
| Avg. volume | 2,063,827 |
| Market cap | 4.037B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 7.80 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
- PR Newswire
Alkermes plc Reports First Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024.
- PR Newswire
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency
